A total of 521 patients with peritoneal carcinomatosis (PC) were treated by peritonectomy and perioperative chemotherapy. Each of the 95, 58, 316, 31, 10 and 11 patients were from gastric, colorectal, appendiceal, ovarian, small bowel cancer and mesothelioma, respectively. The distribution and volume of PC are recorded by the Sugarbaker peritoneal carcinomatosis index (PCI). Peritonectomy was performed with a radical resection of the primary tumor and all gross PC with involved organs, peritoneum, or tissue that was deemed technically feasible and safe for the patient. The postoperative major complication of grade 3 was found in 14%, and total 30-day mortality was 2.7%. The survival of gastric cancer patients with a PCI score ≤ 6 was significantly better than those with a PCI score ≥ 7. In appendiceal neoplasm, patients with PCI score less than 28 showed significantly better survival than those with PCI score greater than 29. The survival of colorectal cancer patients with a PCI score ≥ 11 was significantly poorer than those with a PCI score ≤ 10. Among the various prognostic factors in appendiceal neoplasm and gastric cancer patients, CC-0 complete cytoreduction was the most important independent prognostic factor. Peritonectomy is done to remove macroscopic disease and perioperative intraperitoneal chemotherapy to eradicate microscopic residual disease aiming to remove disease completely with a single procedure. Peritonectomy combined with perioperative chemotherapy may achieve long-term survival in a selected group of patients with PC. The higher mortality rate underlines this necessarily strict selection that should be reserved to experienced institutions.
Download full-text PDF |
Source |
---|
Int J Cardiol Heart Vasc
February 2025
Department of Cardiology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, China.
Background: Thrombolysis in Myocardial Infarction (TIMI) risk score in patients with ST-segment elevation myocardial infarction (STEMI) is associated with major adverse cardiovascular events (MACE). This study aimed to develop a prediction model based on the TIMI risk score for MACE in STEMI patients after percutaneous coronary intervention (PCI).
Methods: We conducted a retrospective data analysis on 290 acute STEMI patients admitted to the Affiliated Hospital of Yangzhou University from January 2022 to June 2023 and met the inclusion criteria.
Rev Cardiovasc Med
January 2025
Department of Cardiology, Renmin Hospital of Wuhan University, 430060 Wuhan, Hubei, China.
Background: Ceramide, a key molecule in sphingolipid metabolism, is recognized as a standalone predictor of long-term major adverse cardiac events (MACE). We explore if integrating the global registry of acute coronary events (GRACE) score with the ceramide risk score (ceramide test 1, CERT1) improves MACE prediction in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
Methods: This cohort study included 210 participants with ACS undergoing PCI.
Curr Oncol
January 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
(1) Background: This pilot study evaluates the feasibility and preliminary effects of acupuncture for cancer-related cognitive dysfunction (CRCD) in cancer survivors. (2) Methods: A randomized trial comparing real acupuncture (RA) to sham acupuncture (SA) and waitlist control (WLC) among cancer survivors reporting cognitive difficulties. Interventions were delivered weekly over 10 weeks.
View Article and Find Full Text PDFJ Cardiothorac Surg
January 2025
Department of Otorhinolaryngology, The Second Affiliated Hospital of Nanchang University, No. 1, Minde Road, Donghu District, Nanchang City, Jiangxi Province Nanchang, 330006, China.
Objective: To study the effect of heart-collateral-based enlightenment words intervention on anxiety and depression in patients following percutaneous coronary intervention (PCI).
Methods: In this class experimental study, one hundred patients who were hospitalized after PCI from May 2020 to October 2021, were included in this interventional study. They were divided into the test group (n = 50) and the control group (n = 50) based on the random number table.
JACC Cardiovasc Interv
January 2025
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!